People · Operator
Named in public records as an officer, director or promoter · active 2018–2021 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Abcuro, Inc. | — | Biotechnology | Series D+ | $225.9M | $719.4M | 2020 |
| Antios Therapeutics Inc. | — | Pharmaceuticals | Series C | $126.4M | $1.7B | 2021 |
| Stargazer Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $28.5M | $967.8M | 2018 |
Iyona Rajkomar at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Iyona Rajkomar on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Wende Hutton | 1 | 16 |
| John Wagner | 1 | 10 |
| John Edwards | 1 | 8 |
| Richard Gaster | 1 | 7 |
| Jason Hafler | 1 | 6 |
| Craig Gordon | 1 | 6 |
| Martin Edwards | 1 | 5 |
| Julius Knowles | 1 | 5 |
| Gregory Mayes | 1 | 5 |
| NICOLE VITULLO | 1 | 4 |
| John Alexander Martin | 1 | 3 |
| Benjamin Rovinski | 1 | 3 |
| Daniel Curran | 1 | 3 |
| David De Graaf | 1 | 3 |
| Donald McCarthy | 1 | 3 |
| Scott Morenstein | 1 | 2 |
| DAVID CANNER | 1 | 2 |
| Evan Thompson | 1 | 2 |
| Idean Marvasty | 1 | 2 |
| Nanna Luneborg | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.